Phase II Trial of Immunotherapy With Durvalumab (MEDI4736) With Continuous or Intermittent MEK Inhibitor Selumetinib in KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 14 Jul 2017
At a glance
- Drugs Durvalumab (Primary) ; Selumetinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 10 Jul 2017 Planned End Date changed from 1 Jun 2022 to 1 Sep 2022.
- 10 Jul 2017 Planned primary completion date changed from 1 Jun 2022 to 1 Sep 2022.
- 10 Jul 2017 Planned initiation date changed from 1 Jun 2017 to 1 Sep 2017.